EyePoint Pharmaceuticals Inc [NASDAQ: EYPT] closed the trading session at $17.50.
The stocks have a year to date performance of -24.28 percent and weekly performance of -23.55 percent. The stock has been moved at 117.66 percent over the last six months. The stock has performed -20.81 percent around the most recent 30 days and changed -23.45 percent over the most recent 3-months.
If compared to the average trading volume of 925.92K shares, EYPT reached to a volume of 4141778 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about EyePoint Pharmaceuticals Inc [EYPT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EYPT shares is $44.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EYPT stock is a recommendation set at 1.22. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for EyePoint Pharmaceuticals Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on January 22, 2024. While these analysts kept the previous recommendation, Mizuho raised their target price to Buy. The new note on the price target was released on November 02, 2023, representing the official price target for EyePoint Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $33, while Robert W. Baird analysts kept a Outperform rating on EYPT stock.
The Average True Range (ATR) for EyePoint Pharmaceuticals Inc is set at 1.55, with the Price to Sales ratio for EYPT stock in the period of the last 12 months amounting to 18.95. The Price to Book ratio for the last quarter was 3.22, with the Price to Cash per share for the same quarter was set at 6.64.
EYPT stock trade performance evaluation
EyePoint Pharmaceuticals Inc [EYPT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -23.55. With this latest performance, EYPT shares dropped by -20.81% in over the last four-week period, additionally plugging by 117.66% over the last 6 months – not to mention a rise of 255.69% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EYPT stock in for the last two-week period is set at 30.10, with the RSI for the last a single of trading hit 25.71, and the three-weeks RSI is set at 34.02 for EyePoint Pharmaceuticals Inc [EYPT]. The present Moving Average for the last 50 days of trading for this stock 24.10, while it was recorded at 20.80 for the last single week of trading, and 15.95 for the last 200 days.
EyePoint Pharmaceuticals Inc [EYPT]: An insightful look at the core fundamentals
EyePoint Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.39 and a Current Ratio set at 5.45.
EyePoint Pharmaceuticals Inc [EYPT]: Institutional Ownership
The top three institutional holders of EYPT stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in EYPT stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in EYPT stock with ownership which is approximately 5.8386%.
